// App-Quantinova.ai

1743 : Pegylated Interferon-Alfa-2a Induces Complete Hematologic and Molecular Responses with Low Toxicity in Essential Thrombocythemia

Researchers

Presenter

  • Nader Al-Dewik

Principal Investigators

  • Hanadi Rafii El-Ayoubi

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • Hamad Medical Corpor

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myeloid neoplasms

  • Essential thrombocythemia

  • Autoimmune hepatitis

  • Congestive heart failure

  • Renal insufficiency

  • Acute Leukemia

  • Myelofibrosis

  • Depression

  • Venous thrombosis

Biomarkers

  • Breakpoint Cluster Region

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Hydroxyurea

  • Hydroxycarbamide

  • Interferon

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved